• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

UK Cell and Gene Therapy Manufacturing Capability on the Rise


May 05, 2016.

The Cell and Gene Therapy Catapult's survey of GMP cell and gene therapy manufacturing facilities in the UK highlights a number of key changes in the cell and gene therapy manufacturing landscape over the last 12 months, including: 

  • A continued increase in the number of GMP manufacturing facilities; 22 facilities in 2016, rising from 18 in 2015 and 13 in 2014. Of this increase, 3 are gene therapy manufacturing facilities and an additional facility in cell therapy. 

  • An increase in the number of people employed across UK cell and gene therapy manufacturers by a further 20% - from 324 to 391.

  • An increased geographical spread of facilities throughout the UK. New additions for 2016 were based in London, Glasgow, Oxford and Birmingham. 

Keith Thompson, CEO at the Cell and Gene Therapy Catapult, commented: “The data in the 2016 report shows growth across all the markers that we analyse and forecasts a considerable increase again in the next 12 months."


Related Videos